COA & Testing Results
Browse lot-specific certificate records for products in this catalog. Each entry summarizes information shown in a supplied report, including reported purity or content, test date, and report details where available. Open the linked document to review the complete certificate and confirm its lot matches your item.
Lot-specific certificate information
Each listing summarizes selected details shown in a document supplied for that product lot, such as the labeled material, lot number, test date, report details, methods, and reported results where available.
The summaries are a reading aid and do not replace the supplied certificate. Review the linked source document for the full record; results apply only to the sample described, and the source document controls if any details differ. Confirm the lot number against your item.
Search lot-specific documentation
Filter the supplied certificate records by product, lot number, strength, report number, test date, or other text shown in a listing.
Pancragen · 20 mg · Lot 94940
Reported purity
99.001% HPLC
Tested
September 23, 2026
Report ID
40172
The supplied Pure Lab Peptides-branded summary identifies Chromate as the testing laboratory and states that the summary was prepared from an independent third-party source report. It also states the summary is not issued or signed by Chromate; use the original report as the controlling source.
Scope: The document states the results apply only to the tested sample as received. This site has not independently authenticated the report or verified that other inventory matches this lot.
Open supplied two-page PDF summary and analytical evidence ↗
Pancragen · Lot 94940 · Report 40172

RP-HPLC chromatogram · Lot 94940

Cardiogen · 20 mg · Lot 54233
Reported purity
99.768% HPLC
Tested
September 17, 2026
Report ID
39804
The supplied Pure Lab Peptides-branded summary identifies Chromate as the testing laboratory and states that the summary was prepared from an independent third-party source report. It also states the summary is not issued or signed by Chromate; use the original report as the controlling source.
The summary lists report date September 19, 2026, sample ID 39804, and molecular weight 489.48 g/mol. Scope: the document states the results apply only to the tested sample as received. This site has not independently authenticated the report or verified that other inventory matches this lot.
Open supplied two-page PDF summary and analytical evidence ↗
Cardiogen · Lot 54233 · Report 39804

RP-HPLC chromatogram · Lot 54233

Thymulin · 10 mg · Lot 61091
Reported purity
99.410% HPLC
Tested
September 17, 2026
Report ID
39798
The supplied Pure Lab Peptides-branded summary identifies Chromate as the testing laboratory and states that the summary was prepared from an independent third-party source report. It also states the summary is not issued or signed by Chromate; use the original report as the controlling source.
The summary lists report date September 19, 2026, sample ID 39798, CAS 63958-90-7, and molecular weight 858.86 g/mol. Scope: the document states the results apply only to the tested sample as received. This site has not independently authenticated the report or verified that other inventory matches this lot.
Open supplied two-page PDF summary and analytical evidence ↗
Thymulin · Lot 61091 · Report 39798

RP-HPLC chromatogram · Lot 61091

Vesugen · 20 mg · Lot 18854
Reported purity
99.892% HPLC
Tested
September 17, 2026
Report ID
39801
The supplied Pure Lab Peptides-branded summary identifies Chromate as the testing laboratory and states that the summary was prepared from an independent third-party source report. It also states the summary is not issued or signed by Chromate; use the original report as the controlling source.
The summary lists report date September 19, 2026, and sample ID 39801. Scope: the document states the results apply only to the tested sample as received. This site has not independently authenticated the report or verified that other inventory matches this lot.
Open supplied two-page PDF summary and analytical evidence ↗
Vesugen · Lot 18854 · Report 39801

RP-HPLC chromatogram · Lot 18854

Vilon · 20 mg · Lot 93894
Reported purity
99.064% HPLC
Tested
September 17, 2026
Report ID
39802
The supplied Pure Lab Peptides-branded summary identifies Chromate as the testing laboratory and states that the summary was prepared from an independent third-party source report. It also states the summary is not issued or signed by Chromate; use the original report as the controlling source.
The summary lists report date September 19, 2026, sample ID 39802, and CAS 45234-02-4. Scope: the document states the results apply only to the tested sample as received. This site has not independently authenticated the report or verified that other inventory matches this lot.
Open supplied two-page PDF summary and analytical evidence ↗
Vilon · Lot 93894 · Report 39802

RP-HPLC chromatogram · Lot 93894

Gonadorelin · 2 mg · Lot 35188
Reported purity
99.359% HPLC
Tested
September 15, 2026
Report ID
39812
The supplied Pure Lab Peptides-branded summary identifies Chromate as the testing laboratory and states that the summary was prepared from an independent third-party source report. It also states the summary is not issued or signed by Chromate; use the original report as the controlling source.
The summary lists report date September 19, 2026, sample ID 39812, and CAS 33515-09-2. Scope: the document states the results apply only to the tested sample as received. This site has not independently authenticated the report or verified that other inventory matches this lot.
Open supplied two-page PDF summary and analytical evidence ↗
Gonadorelin · Lot 35188 · Report 39812

RP-HPLC chromatogram · Lot 35188

GHRP-2 · 10 mg · Lot 89304
Reported purity
99.030% HPLC
Tested
September 14, 2026
Report ID
39709
The supplied Pure Lab Peptides-branded summary identifies Chromate as the testing laboratory and states that the summary was prepared from an independent third-party source report. It also states the summary is not issued or signed by Chromate; use the original report as the controlling source.
The summary lists report date September 14, 2026, sample ID 39709, CAS 158861-67-7, and molecular weight 817.99 g/mol. Scope: the document states the results apply only to the tested sample as received. This site has not independently authenticated the report or verified that other inventory matches this lot.
Open supplied two-page PDF summary and analytical evidence ↗
GHRP-2 · Lot 89304 · Report 39709

RP-HPLC chromatogram · Lot 89304

GHRP-6 · 10 mg · Lot 71556
Reported purity
99.270% HPLC
Tested
September 14, 2026
Report ID
39707
The supplied Pure Lab Peptides-branded summary identifies Chromate as the testing laboratory and states that the summary was prepared from an independent third-party source report. It also states the summary is not issued or signed by Chromate; use the original report as the controlling source.
The summary lists report date September 14, 2026, sample ID 39707, CAS 87616-84-0, and molecular weight 873.03 g/mol. Scope: the document states the results apply only to the tested sample as received. This site has not independently authenticated the report or verified that other inventory matches this lot.
Open supplied two-page PDF summary and analytical evidence ↗
GHRP-6 · Lot 71556 · Report 39707

RP-HPLC chromatogram · Lot 71556

GHRP-6 · 5 mg · Lot 86442
Reported purity
99.080% HPLC
Tested
September 14, 2026
Report ID
39706
The supplied Pure Lab Peptides-branded summary identifies Chromate as the testing laboratory and states that the summary was prepared from an independent third-party source report. It also states the summary is not issued or signed by Chromate; use the original report as the controlling source.
The summary lists report date September 14, 2026, sample ID 39706, CAS 87616-84-0, and molecular weight 873.03 g/mol. Scope: the document states the results apply only to the tested sample as received. This site has not independently authenticated the report or verified that other inventory matches this lot.
Open supplied two-page PDF summary and analytical evidence ↗
GHRP-6 · Lot 86442 · Report 39706

RP-HPLC chromatogram · Lot 86442

Adamax · 10 mg · Lot 58026
Reported purity
99.564% HPLC
Tested
September 13, 2026
Report ID
39662
The supplied Pure Lab Peptides-branded summary identifies Chromate as the testing laboratory and states that the summary was prepared from an independent third-party source report. It also states the summary is not issued or signed by Chromate; use the original report as the controlling source.
The summary lists report date September 13, 2026, sample ID 39662, CAS not available, and molecular weight 1032.22 g/mol. Scope: the document states the results apply only to the tested sample as received. This site has not independently authenticated the report or verified that other inventory matches this lot.
Open supplied two-page PDF summary and analytical evidence ↗
Adamax · Lot 58026 · Report 39662

RP-HPLC chromatogram · Lot 58026

5-Amino-1MQ · 10 mg · Lot 61611
Reported HPLC purity
99.8%
Date tested
August 11, 2026
BTLabs report
COA261057-011
Potency result: 11.8 mg (118.4%) against the certificate-stated 90–110% of 10 mg specification. This reported value is above that stated range. The certificate also reports a peptide-to-excipients ratio of 1:5.2. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
AOD-9604 · 5 mg · Lot 99766
Reported HPLC purity
99.7%
Date tested
August 11, 2026
BTLabs report
COA261057-024
The certificate reports potency of 4.8 mg (95.5%) against a 90–110% specification, and a peptide-to-excipients ratio of 1:13.9 versus the stated recommended range of 1:2 to 1:10. The ratio is outside that recommendation. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Bacteriostatic Water · 10 mL · Lot 11538
Reported HPLC purity
99.7%
Date tested
August 11, 2026
BTLabs report
COA261057-028
The certificate reports potency of 8.9 mg (99.7%) and states that its testing does not assess particulate matter, microbial contamination, or endotoxins. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Cagrilintide · 5 mg · Lot 66516
Reported HPLC purity
99.7%
Date tested
August 11, 2026
BTLabs report
COA261057-023
Potency result: 5.6 mg (112.6%) against a stated 90–110% specification, above that range. The certificate also reports a peptide-to-excipients ratio of 1:15.4 versus the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Cartalax · 20 mg · Lot 17421
Reported HPLC purity
99.6%
Date tested
August 11, 2026
BTLabs report
COA261057-015
The certificate reports potency of 19.9 mg (99.7%) against a 90–110% specification and a peptide-to-excipients ratio of 1:3.1 against the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
CJC-1295 DAC · 2 mg · Lot 13878
Reported HPLC purity
99.6%
Date tested
August 11, 2026
BTLabs report
COA261057-026
The certificate reports potency of 2.1 mg (104.8%) against a 90–110% specification, and a peptide-to-excipients ratio of 1:20.4 versus the stated recommended range of 1:2 to 1:10. The ratio is outside that recommendation. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
CJC-1295 no-DAC · 2 mg · Lot 70803
Reported HPLC purity
99.6%
Date tested
August 11, 2026
BTLabs report
COA261057-025
Potency result: 2.3 mg (116.1%) against a stated 90–110% specification, above that range. The certificate also reports a peptide-to-excipients ratio of 1:16.1 versus the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Cortagen · 20 mg · Lot 14405
Reported HPLC purity
99.7%
Date tested
August 11, 2026
BTLabs report
COA261057-017
The certificate reports potency of 19.4 mg (96.9%) against a 90–110% specification, and a peptide-to-excipients ratio of 1:3.2 against the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Kisspeptin · 10 mg · Lot 79548
Reported HPLC purity
99.9%
Date tested
August 11, 2026
BTLabs report
COA261057-013
Potency result: 11.3 mg (113.1%) against a stated 90–110% specification, above that range. The certificate reports a peptide-to-excipients ratio of 1:5.2 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
KLOW · 80 mg · Lot 33414
Reported HPLC purity
99.8%
Date tested
August 11, 2026
BTLabs report
COA261057-003
The certificate reports component assay results: GHK-Cu 48.9 mg (61.1%), KPV 12.6 mg (15.8%), BPC-157 12.7 mg (15.9%), and TB-500 8.4 mg (10.4%). It reports a peptide-to-excipients ratio of 1:1 versus its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Melanotan II · 10 mg · Lot 74928
Reported HPLC purity
99.9%
Date tested
August 11, 2026
BTLabs report
COA261057-006
The certificate reports potency of 10.6 mg (106.2%) against a 90–110% specification, and a peptide-to-excipients ratio of 1:5.8 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
MOTS-c · 10 mg · Lot 26394
Reported HPLC purity
99.8%
Date tested
August 11, 2026
BTLabs report
COA261057-004
The certificate reports potency of 9.9 mg (99.5%) against a 90–110% specification and a peptide-to-excipients ratio of 1:6.6 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
MOTS-c · 20 mg · Lot 30294
Reported HPLC purity
99.9%
Date tested
August 11, 2026
BTLabs report
COA261057-012
Potency result: 24.7 mg (123.7%) against a stated 90–110% specification, above that range. The certificate reports a peptide-to-excipients ratio of 1:2 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
MOTS-c · 40 mg · Lot 11342
Reported HPLC purity
99.9%
Date tested
August 11, 2026
BTLabs report
COA261057-005
Potency result: 46 mg (115.1%) against a stated 90–110% specification, above that range. The certificate also reports a peptide-to-excipients ratio of 1:1.3 versus its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
NAD · 500 mg · Lot 31758
Reported HPLC purity
99.9%
Date tested
August 11, 2026
BTLabs report
COA261057-027
Potency result: 586.6 mg (117.3%) against a stated 90–110% specification, above that range. The certificate reports a peptide-to-excipients ratio of 1:0.4 versus its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Ovagen · 20 mg · Lot 67774
Reported HPLC purity
99.6%
Date tested
August 11, 2026
BTLabs report
COA261057-020
The certificate reports potency of 21.4 mg (106.8%) against a 90–110% specification and a peptide-to-excipients ratio of 1:2.8 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Ovagen · 20 mg · Lot 74421
Reported HPLC purity
99.6%
Date tested
August 11, 2026
BTLabs report
COA261057-019
The certificate reports potency of 21.1 mg (105.5%) against a 90–110% specification and a peptide-to-excipients ratio of 1:2.8 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Pinealon · 20 mg · Lot 70114
Reported HPLC purity
99.7%
Date tested
August 11, 2026
BTLabs report
COA261057-022
The certificate reports potency of 21.4 mg (107.2%) against a 90–110% specification and a peptide-to-excipients ratio of 1:3 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Selank · 5 mg · Lot 61489
Reported HPLC purity
99.9%
Date tested
August 11, 2026
BTLabs report
COA261057-007
The certificate reports potency of 4.8 mg (96.4%) against a 90–110% specification and a peptide-to-excipients ratio of 1:12.7 versus its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
SS-31 · 50 mg · Lot 99768
Reported HPLC purity
99.8%
Date tested
August 11, 2026
BTLabs report
COA261057-010
The certificate reports potency of 52 mg (104%) against a 90–110% specification and a peptide-to-excipients ratio of 1:2.3 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
ARA-290 · 16 mg · Lot 12183
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-01
The certificate reports potency of 16.8 mg (105.1%) against a 90–110% specification and a peptide-to-excipients ratio of 1:4 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
BPC-157 · 10 mg · Lot 58825
Reported HPLC purity
99.6%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-05
The certificate reports potency of 9.7 mg (97.3%) against a 90–110% specification and a peptide-to-excipients ratio of 1:7.4 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
BPC-157 · 5 mg · Lot 99716
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-06
The certificate reports potency of 4.7 mg (99.7%) against a 90–110% specification and a peptide-to-excipients ratio of 1:14.2 versus its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
CJC-1295 DAC · 5 mg · Lot 94072
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-07
Potency result: 5.6 mg (112.5%) against a stated 90–110% specification, above that range. The certificate reports a peptide-to-excipients ratio of 1:8 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
CJC-1295 no-DAC · 5 mg · Lot 99719
Reported HPLC purity
99.5%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-10
The certificate reports potency of 5.3 mg (105.6%) against a 90–110% specification and a peptide-to-excipients ratio of 1:8.7 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GHK-Cu · 50 mg · Lot 83075
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-12
The certificate reports potency of 50.6 mg (101.2%) against a 90–110% specification and a peptide-to-excipients ratio of 1:1.8 versus its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLOW · 70 mg · Lot 99751
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-14
The certificate reports component assay results: GHK-Cu 50.3 mg (71.9%), BPC-157 11.5 mg (16.5%), and TB-500 10.2 mg (14.5%). It reports a peptide-to-excipients ratio of 1:1.1 versus the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLOW · 70 mg · Lot 99723
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-13
The certificate reports component assay results: GHK-Cu 49.7 mg (71%), BPC-157 10 mg (14.3%), and TB-500 12.1 mg (17.3%). It reports a peptide-to-excipients ratio of 1:1.7 versus the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP1-S / Semaglutide · 20 mg · Lot 99756
Reported HPLC purity
99.9%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-17
The certificate reports potency of 20.7 mg (103.5%) against a 90–110% specification and a peptide-to-excipients ratio of 1:2.4 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP1-S / Semaglutide · 20 mg · Lot 99725
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-16
The certificate reports potency of 20.2 mg (101.2%) against a 90–110% specification and a peptide-to-excipients ratio of 1:2.6 against its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP1-S / Semaglutide · 20 mg · Lot 99756 · Report 45
Reported HPLC purity
99.9%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-45
This is a second supplied report for lot 99756, with a different BT Sample ID and report number from the other lot 99756 certificate. It reports potency of 20.6 mg (102.8%) and a peptide-to-excipients ratio of 1:2.5, within the stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP1-S / Semaglutide · 5 mg · Lot 13422
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-43
The certificate reports potency of 5.5 mg (110.8%), above its stated 90–110% specification; the peptide-to-excipients ratio is 1:8, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP2-T / Tirzepatide · 5 mg · Lot 99726
Reported HPLC purity
99.6%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-46
The certificate reports potency of 5.1 mg (102.2%) within its 90–110% specification. Its 1:17.3 peptide-to-excipients ratio is outside the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP2-T / Tirzepatide · 10 mg · Lot 45543
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-47
The certificate reports potency of 10.3 mg (102.8%) and a peptide-to-excipients ratio of 1:8.9, both within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP2-T / Tirzepatide · 15 mg · Lot 97890
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-48
The certificate reports potency of 17 mg (113.5%), above its stated 90–110% specification; the peptide-to-excipients ratio is 1:5.7, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP2-T / Tirzepatide · 30 mg · Lot 99763
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-49
The certificate reports potency of 34.5 mg (115.1%), above its stated 90–110% specification. Its 1:1.3 peptide-to-excipients ratio is below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP2-T / Tirzepatide · 60 mg · Lot 99764
Reported HPLC purity
99.9%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-50
The certificate reports potency of 70.4 mg (117.3%), above its stated 90–110% specification. Its 1:0.7 peptide-to-excipients ratio is below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP2-T / Tirzepatide · 90 mg · Lot 99765
Reported HPLC purity
99.9%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-51
The certificate reports potency of 93.7 mg (104.1%) within its stated 90–110% specification. Its 1:0.6 peptide-to-excipients ratio is below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 10 mg · Lot 99760
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-53
The certificate reports potency of 10.1 mg (101.4%) and a peptide-to-excipients ratio of 1:8.7, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 10 mg · Lot 80403
Reported HPLC purity
99.6%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-54
The certificate reports potency of 10.8 mg (108.2%) and a peptide-to-excipients ratio of 1:6, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 20 mg · Lot 99761
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-55
The certificate reports potency of 21 mg (104.9%) and a peptide-to-excipients ratio of 1:3.3, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 20 mg · Lot 74215
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-56
The certificate reports potency of 20.5 mg (102.4%) and a peptide-to-excipients ratio of 1:4.3, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 30 mg · Lot 99762
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-57
The certificate reports potency of 30.5 mg (101.6%) and a peptide-to-excipients ratio of 1:3.3, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 30 mg · Lot 46633
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-58
The certificate reports potency of 30.3 mg (100.9%) and a peptide-to-excipients ratio of 1:3.2, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 40 mg · Lot 44884
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-59
The certificate reports potency of 44.3 mg (110.6%), slightly above its stated 90–110% specification. Its 1:1.7 peptide-to-excipients ratio is below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP2-T / Tirzepatide · 10 mg · Lot 73023
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-60
The certificate reports potency of 10.8 mg (107.8%) and a peptide-to-excipients ratio of 1:8.7, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 5 mg · Lot 99759
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-52
The certificate reports potency of 5.8 mg (116.7%), above its stated 90–110% specification; the peptide-to-excipients ratio is 1:8.1, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Ipamorelin · 10 mg · Lot 99754
Reported HPLC purity
99.9%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-20
The certificate reports potency of 11.8 mg (117.9%), above its stated 90–110% specification; the peptide-to-excipients ratio is 1:3.8, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Ipamorelin · 5 mg · Lot 99733
Reported HPLC purity
99.9%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-21
The certificate reports potency of 5.3 mg (106.8%) and a peptide-to-excipients ratio of 1:9.1, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
MOTS-C · 40 mg · Lot 99753
Reported HPLC purity
99.9%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-28
The certificate reports potency of 49.1 mg (122.9%), above its stated 90–110% specification. Its 1:1.7 peptide-to-excipients ratio is below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Selank · 10 mg · Lot 49223
Reported HPLC purity
99.6%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-29
The certificate reports potency of 12.2 mg (121.9%), above its stated 90–110% specification; the peptide-to-excipients ratio is 1:5.3, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Semax · 10 mg · Lot 53308
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-31
The certificate reports potency of 11.7 mg (117%), above its stated 90–110% specification; the peptide-to-excipients ratio is 1:5.9, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Sermorelin · 5 mg · Lot 99708
Reported HPLC purity
99.6%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-33
The certificate reports potency of 5.2 mg (103.3%) within its stated 90–110% specification. Its 1:12.6 peptide-to-excipients ratio is outside the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
SS-31 · 10 mg · Lot 54604
Reported HPLC purity
99.9%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-34
The certificate reports potency of 11.5 mg (115.2%), above its stated 90–110% specification; the peptide-to-excipients ratio is 1:5.9, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
TB-500 · 10 mg · Lot 49089
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-36
The certificate reports potency of 12.4 mg (124.3%), above its stated 90–110% specification; the peptide-to-excipients ratio is 1:5.2, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
TB-500 · 10 mg · Lot 97379
Reported HPLC purity
99.8%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-37
The certificate reports potency of 11.1 mg (110.9%), slightly above its stated 90–110% specification; the peptide-to-excipients ratio is 1:5.5, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Tesamorelin · 5 mg · Lot 99750
Reported HPLC purity
99.7%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-40
The certificate reports potency of 5.5 mg (110.8%), above its stated 90–110% specification. Its 1:13.8 peptide-to-excipients ratio is outside the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Tesamorelin / Ipamorelin · 10 mg · Lot 99747
Reported HPLC purity
99.9%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-41
The certificate reports separate component potency results: Ipamorelin 5.8 mg (58.5%) and Tesamorelin 6.2 mg (61.7%) against a 10 mg specification. It reports total peptide-to-excipients ratio 1:4.7 within the stated ratio range. The two individual percentages are presented as printed on the source. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Tri-Heal · 45 mg · Lot 99712
Reported HPLC purity
99.6%
Date tested
July 15, 2026
BTLabs report
IF-824-QSA-TR006-BTL26955-42
The certificate lists component assay results: KPV 11.9 mg (26.4%), BPC-157 11.5 mg (25.6%), and TB-500 27.8 mg (60.8%). It reports a peptide-to-excipients ratio of 1:1.9, below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
5-Amino-1MQ · 50 mg · Lot 54697
Reported HPLC purity
99.5%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-01
The certificate reports potency of 47.2 mg (94.5%) against a stated 90–110% specification and a peptide-to-excipients ratio of 1:2.6. The certificate lists PureLab Peptides as both customer and manufacturer. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
ARA-290 · 16 mg · Lot 20560
Reported HPLC purity
99.7%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-07
The certificate reports potency of 16.3 mg (101.8%) and a peptide-to-excipients ratio of 1:3.4, within its stated ranges. The certificate lists PureLab Peptides as both customer and manufacturer. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
BPC-157 / TB-500 · 10 mg · Lot 65192
Reported HPLC purity
99.8%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-08
The certificate lists component assays: BPC-157 5.9 mg (58.6%) and TB-500 6.03 mg (60.3%). It reports a peptide-to-excipients ratio of 1:5.2. The certificate lists PureLab Peptides as both customer and manufacturer. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
BPC-157 / TB-500 · 20 mg · Lot 48182
Reported HPLC purity
99.8%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-09
The certificate lists component assays: BPC-157 11.4 mg (57.1%) and TB-500 11.7 mg (58.3%). It reports a peptide-to-excipients ratio of 1:2.7. The certificate lists PureLab Peptides as both customer and manufacturer. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Cagrilintide · 5 mg · Lot 14106
Reported HPLC purity
99.8%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-10
The certificate reports potency of 6 mg (119.1%), above its stated 90–110% specification. Its 1:15 peptide-to-excipients ratio is outside the stated recommended range of 1:2 to 1:10. The certificate lists PureLab Peptides as both customer and manufacturer. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Chonluten · 20 mg · Lot 57568
Reported HPLC purity
99.4%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-12
The certificate reports potency of 22.2 mg (110.8%), above its stated 90–110% specification, and a peptide-to-excipients ratio of 1:2.3. The certificate lists PureLab Peptides as both customer and manufacturer. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 20 mg · Lot 46743
Reported HPLC purity
99.7%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-14
The certificate reports potency of 19.8 mg (99.1%) and a peptide-to-excipients ratio of 1:5.1. The certificate lists PureLab Peptides as both customer and manufacturer; the supplied filename identifies this as GLP3-R. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
KPV · 10 mg · Lot 57460
Reported HPLC purity
99.5%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-13
The certificate reports potency of 11.1 mg (110.6%), slightly above its stated 90–110% specification. Its peptide-to-excipients ratio is 1:6, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Semax · 10 mg · Lot 22823
Reported HPLC purity
99.8%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-16
The certificate reports potency of 10.5 mg (104.6%) and a peptide-to-excipients ratio of 1:6.1, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Semax · 5 mg · Lot 11376
Reported HPLC purity
99.7%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-15
The certificate reports potency of 5.1 mg (101.9%) and a peptide-to-excipients ratio of 1:9.1, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
SLU-PP-332 · 5 mg · Lot 70353-B
Reported HPLC purity
99.2%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-03
The certificate reports potency of 5 mg (100.6%) within its 90–110% specification. Its 1:17.7 peptide-to-excipients ratio is outside the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Tesamorelin · 5 mg · Lot 57573
Reported HPLC purity
99.6%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-04
The certificate reports potency of 5.5 mg (110.8%), above its stated 90–110% specification; the peptide-to-excipients ratio is 1:8.2, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
VIP · 10 mg · Lot 21699
Reported HPLC purity
99.7%
Date tested
March 18, 2026
BTLabs report
IF-824-QSA-TR006-BTL2649-06
The certificate reports potency of 10.8 mg (108.3%) and a peptide-to-excipients ratio of 1:3.9, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
5-Amino-1MQ · 10 mg · Lot 46721
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-01
The certificate reports potency of 10.7 mg (106.9%) and a peptide-to-excipients ratio of 1:4.2, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
AICAR · 50 mg · Lot 70957
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-02
The certificate reports potency of 53.7 mg (107.4%) within its stated 90–110% specification. Its 1:0.9 peptide-to-excipients ratio is below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
AOD-9604 · 5 mg · Lot 97508
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-03
The certificate reports potency of 5.5 mg (109.1%) and a peptide-to-excipients ratio of 1:7.5, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Cagrilintide / Semaglutide · 10 mg · Lot 27161
Reported HPLC purity
99.5%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-01
The certificate reports component potency values of Cagrilintide 5.8 mg (58.3%) and Semaglutide 4.9 mg (48.5%) against the 10 mg blend label. It reports a combined peptide-to-excipients ratio of 1:6.2, within its stated ratio range; component values are shown as printed. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Cagrilintide · 10 mg · Lot 79433
Reported HPLC purity
99.8%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-09
The certificate reports potency of 10.8 mg (107.6%) and a peptide-to-excipients ratio of 1:3.5, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
CJC-1295 DAC · 5 mg · Lot 56991
Reported HPLC purity
99.8%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-15
The certificate reports potency of 6.2 mg (124.5%), above its stated 90–110% specification. The peptide-to-excipients ratio is 1:8.7, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
CJC-1295 no-DAC / Ipamorelin · 10 mg blend · Lot 83775
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-14
The certificate reports separate component potency results: Ipamorelin 5.2 mg (51.6%) and CJC-1295 6.9 mg (69.1%) against the 10 mg blend label. It reports a peptide-to-excipients ratio of 1:4.8. Component values are listed as printed in the source. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
CJC-1295 no-DAC · 5 mg · Lot 29563
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-13
The certificate reports potency of 5.1 mg (102.1%) and a peptide-to-excipients ratio of 1:8.9, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Cortagen · 20 mg · Lot 59968
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-71
The certificate reports potency of 21 mg (105.1%) within its stated 90–110% specification. Its peptide-to-excipients ratio is 1:1.9, below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
DSIP · 10 mg · Lot 25817
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-16
The certificate reports potency of 10.1 mg (100.8%) and a peptide-to-excipients ratio of 1:4.3, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
DSIP · 5 mg · Lot 78142
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-17
The certificate reports potency of 5 mg (99.4%) and a peptide-to-excipients ratio of 1:9.1, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Epithalon · 10 mg · Lot 72578
Reported HPLC purity
99.6%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-18
The certificate reports potency of 11.8 mg (118.3%), above its stated 90–110% specification. Its peptide-to-excipients ratio is 1:3.6, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GHK-Cu · 100 mg · Lot 53981
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-19
The certificate reports potency of 108.3 mg (108.3%) within its stated 90–110% specification. Its 1:1.1 peptide-to-excipients ratio is below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GHK-Cu · 50 mg · Lot 56463
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-20
The certificate reports potency of 59.6 mg (119.2%), above its stated 90–110% specification. Its peptide-to-excipients ratio is 1:2.6, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLOW · 70 mg · Lot 63250
Reported HPLC purity
99.6%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-21
The certificate lists component assays: GHK-Cu 61.2 mg (87.4%), BPC-157 7.4 mg (10.6%), and TB-500 5.2 mg (7.5%). It reports a peptide-to-excipients ratio of 1:1.2, below the stated recommended range of 1:2 to 1:10. Values are presented as printed in the report. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP1-S / Semaglutide · 10 mg · Lot 30195
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-45
The certificate reports potency of 9.5 mg (95%) and a peptide-to-excipients ratio of 1:4.8, within its stated ranges. The supplied filename identifies the record as GLP1-S. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP1-S / Semaglutide · 20 mg · Lot 25765
Reported HPLC purity
99.8%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-46
The certificate reports potency of 20.2 mg (101.2%) and a peptide-to-excipients ratio of 1:2.9, within its stated ranges. The supplied filename identifies the record as GLP1-S. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP2-T / Tirzepatide · 10 mg · Lot 45543 · Report 63
Reported HPLC purity
99.6%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-63
This is a second supplied report for lot 45543, with a distinct report number and BT Sample ID from the other listed lot 45543 certificate. It reports potency of 9.9 mg (99%) and a peptide-to-excipients ratio of 1:8.7, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP2-T / Tirzepatide · 30 mg · Lot 37539
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-65
The certificate reports potency of 33.9 mg (113.2%), above its stated 90–110% specification. The peptide-to-excipients ratio is 1:2.8, within its stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP2-T / Tirzepatide · 5 mg · Lot 98146
Reported HPLC purity
99.5%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-66
The certificate reports potency of 5.4 mg (108%) within its stated 90–110% specification. Its 1:15.5 peptide-to-excipients ratio is outside the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 10 mg · Lot 80403 · Report 38
Reported HPLC purity
99.6%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-38
This is a distinct supplied report for lot 80403 with a different report number and BT Sample ID from the other listed certificate. It reports potency of 10.4 mg (104.4%) and a peptide-to-excipients ratio of 1:6.8, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 20 mg · Lot 74215 · Report 39
Reported HPLC purity
99.8%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-39
This is a distinct supplied report for lot 74215 with a different report number and BT Sample ID from the other listed certificate. It reports potency of 21 mg (105.2%) and a peptide-to-excipients ratio of 1:4.4, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 30 mg · Lot 46633 · Report 40
Reported HPLC purity
99.6%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-40
This is a distinct supplied report for lot 46633 with a different report number and BT Sample ID from the other listed certificate. It reports potency of 29.4 mg (98.2%) and a peptide-to-excipients ratio of 1:3.3, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 50 mg · Lot 21549
Reported HPLC purity
99.8%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-42
The certificate reports potency of 53.4 mg (106.8%) within its stated 90–110% specification. Its 1:1 peptide-to-excipients ratio is below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
GLP3-R / Retatrutide · 5 mg · Lot 85555
Reported HPLC purity
99.4%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-41
The certificate reports potency of 4.8 mg (95.4%) and a 1:21.8 peptide-to-excipients ratio, outside its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Ipamorelin · 10 mg · Lot 84704
Reported HPLC purity
99.8%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-22
The certificate reports potency of 10 mg (100.1%) and a peptide-to-excipients ratio of 1:9.7, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Ipamorelin · 5 mg · Lot 51036
Reported HPLC purity
99.8%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-23
The certificate reports potency of 5.3 mg (105.4%) within its 90–110% specification. Its 1:18.6 peptide-to-excipients ratio is outside the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Kisspeptin · 10 mg · Lot 80694
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-24
The certificate reports potency of 10.2 mg (101.9%) and a peptide-to-excipients ratio of 1:6.6, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
KLOW · 80 mg · Lot 78928
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-25
The certificate lists component assays: GHK-Cu 62.2 mg (77.7%), KPV 8.9 mg (11.2%), BPC-157 10.8 mg (13.5%), and TB-500 9.2 mg (11.5%). Its 1:1.9 peptide-to-excipients ratio is below the stated recommended range of 1:2 to 1:10. Values are shown as printed in the report. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
MOTS-C · 10 mg · Lot 60100
Reported HPLC purity
99.8%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-31
The certificate reports potency of 10.5 mg (104.9%) and a peptide-to-excipients ratio of 1:6.7, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Melanotan II · 10 mg · Lot 28174
Reported HPLC purity
99.5%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-30
The certificate reports potency of 10.7 mg (107.5%) and a peptide-to-excipients ratio of 1:4.6, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Melanotan I · 10 mg · Lot 22186
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-29
The certificate reports potency of 10.4 mg (103.7%) and a peptide-to-excipients ratio of 1:4.6, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Mazdutide · 5 mg · Lot 98385
Reported HPLC purity
99.6%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-28
The certificate reports potency of 5.4 mg (108.5%) within its stated 90–110% specification. Its 1:12.3 peptide-to-excipients ratio is outside the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Mazdutide · 10 mg · Lot 56636
Reported HPLC purity
99.5%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-27
The certificate reports potency of 11.1 mg (110.7%), slightly above its stated 90–110% specification. The peptide-to-excipients ratio is 1:6.3, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
MOTS-C · 20 mg · Lot 52610
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-32
The certificate reports potency of 22.5 mg (112.4%), above its stated 90–110% specification; the peptide-to-excipients ratio is 1:2.7, within its stated recommendation. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
MOTS-C · 40 mg · Lot 39542
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-33
The certificate reports potency of 42.9 mg (107.3%) within its stated 90–110% specification. Its 1:1.5 peptide-to-excipients ratio is below the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
NAD · 500 mg · Lot 45018
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-74
The certificate reports potency of 482.5 mg (96.5%) against its stated 90–110% specification and a peptide-to-excipients ratio of 1:0.3, below its stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Oxytocin · 10 mg · Lot 73586
Reported HPLC purity
99.4%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-34
The certificate reports potency of 10.7 mg (106.8%) and a peptide-to-excipients ratio of 1:6.4, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Oxytocin · 5 mg · Lot 66263
Reported HPLC purity
99.6%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-35
The certificate reports potency of 4.9 mg (98.8%) and a peptide-to-excipients ratio of 1:10, at the upper end of its stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
TB-500 · 10 mg · Lot 90244
Reported HPLC purity
99.3%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-57
The certificate reports potency of 10.3 mg (102.5%) and a peptide-to-excipients ratio of 1:6, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Survodutide · 10 mg · Lot 46798
Reported HPLC purity
99.4%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-56
The certificate reports potency of 9.8 mg (98.2%) and a peptide-to-excipients ratio of 1:6, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
SS-31 · 30 mg · Lot 92477
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-54
The certificate reports potency of 35.2 mg (117.2%), above its stated 90–110% specification. The peptide-to-excipients ratio of 1:2 is within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
SS-31 · 10 mg · Lot 14476
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-53
The certificate reports potency of 10.8 mg (108.5%) and a peptide-to-excipients ratio of 1:5.5, within its stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Sermorelin · 5 mg · Lot 57243
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-51
The certificate reports potency of 4.8 mg (95%) within its stated 90–110% specification. Its 1:13.3 peptide-to-excipients ratio is outside the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Tri-Heal · 45 mg · Lot 78609
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-67
The report lists KPV 10.5 mg (23.4%), BPC-157 10.6 mg (23.5%), and TB-500 22.4 mg (49.8%). The listed total is 43.5 mg against a 45 mg label claim. Its peptide-to-excipients ratio is 1:1.4, outside the stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Tesamorelin / Ipamorelin · 10 mg · Lot 63747
Reported HPLC purity
99.9%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-62
The report lists Ipamorelin 5.5 mg (55.3%) and Tesamorelin 5.8 mg (57.5%), totaling 11.3 mg against a 10 mg label claim, above the stated 90–110% potency specification. The peptide-to-excipients ratio is 1:5.4, within the stated recommended range. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Tesamorelin · 20 mg · Lot 80804
Reported HPLC purity
99.8%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-60
The certificate reports potency of 21.1 mg (105.5%) and a peptide-to-excipients ratio of 1:2.7, both within the report’s stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Tesamorelin · 10 mg · Lot 81625
Reported HPLC purity
99.7%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-59
The certificate reports potency of 10.9 mg (109.3%) and a peptide-to-excipients ratio of 1:4.9, within the report’s stated ranges. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
TB-500 · 5 mg · Lot 42601
Reported HPLC purity
99.1%
Date tested
March 2, 2026
BTLabs report
IF-824-QSA-TR006-2026-127-58
The certificate reports potency of 5.4 mg (108.7%), within its stated 90–110% specification. Its 1:19.8 peptide-to-excipients ratio is outside the report’s stated recommended range of 1:2 to 1:10. Results apply only to the sample as received; this site has not independently authenticated the report or matched other inventory to this lot.
Document provenance
These images were supplied by the store owner. The certificate summary is branded Pure Lab Peptides, and the source itself attributes laboratory testing to Chromate. Branding and laboratory attribution are shown as supplied; this site is independently operated.
The summary shows a QR code and source-report access information. Confirm the full source report and confirm the lot identity against your inventory before relying on this record. The chromatogram page states its source image was extracted from the original report.
Documentation questions: info@officialpurepeptides.com · (551) 327-6314.